NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU). Shareholders who purchased shares of CRBU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/caribou-biosciences-inc-loss-submission-form/?id=122791&from=3 CLASS PER ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Caribou To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Caribou between July 14, 2023 and July 16, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Jan. 15, 2025 /PRNewswire/ -- ...

NEW YORK, Jan. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou Biosciences, Inc." or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Caribou Biosciences, Inc. investors who were adversely affected by alleged securities fraud between July 14, 2023 and July 16, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ ...

Company Overview - Caribou Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for treating hematologic malignancies in the US and internationally [3] Financial and Operational Developments - On July 16 2024 Caribou disclosed in an SEC filing that it discontinued preclinical research activities associated with its allogeneic CAR-NK platform and reduced its workforce by 21 positions or approximately 12% to extend its cash runway [1] - Following this announcement Caribou's stock price fell 33% to close at $264 per share on July 17 2024 [1] Clinical Trial and Product Updates - On June 2 2024 Caribou issued a press release announcing updated clinical data from the ongoing ANTLER Phase 1 trial indicating that a single dose of CB-010 has the potential to rival the safety efficacy and durability of approved autologous CAR-T cell therapies [6] - In response to this announcement Evercore ISI analysts downgraded Caribou stock to "in line" and dropped their price target to $300 from $1300 [6] - Caribou's stock price fell 2552% to close at $2145 per share on June 3 2024 following the announcement [6] Legal and Regulatory Matters - A class action lawsuit was filed on behalf of all persons and entities that purchased or otherwise acquired Caribou Biosciences Inc securities between July 14 2023 and July 16 2024 [3] - The complaint alleges that Caribou misled investors regarding the efficacy of its lead drug candidate CB-010 overstating its safety efficacy and durability relative to approved autologous CAR-T cell therapies [4] - The complaint also alleges that Caribou failed to disclose significant risks of insufficient cash liquidity and capital to fund its current business operations including preclinical research activities associated with the allogeneic CAR-NK platform [4] - Shareholders who want to serve as lead plaintiff for the class must submit their application to the court by February 24 2025 [5]

NEW YORK, Jan. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU).Shareholders who purchased shares of CRBU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/caribou-biosciences-inc-loss-submission-form/?id=122000&from=4CLASS PERIOD: Jul ...

Clinical Trials and Programs - Caribou Biosciences initiated the GALLOP Phase 1 clinical trial for CB-010 in patients with lupus nephritis (LN) and extrarenal lupus (ERL) [1][5] - The AMpLify Phase 1 trial for CB-012 in relapsed or refractory acute myeloid leukemia (r/r AML) completed dose level 3 with no dose-limiting toxicities (DLTs) and is enrolling patients at dose level 4 [1][11] - Clinical data from the ANTLER Phase 1 trial for CB-010 in second-line large B cell lymphoma (2L LBCL) and the CaMMouflage Phase 1 trial for CB-011 in relapsed or refractory multiple myeloma (r/r MM) are expected in H1 2025 [1][12] - Caribou plans to initiate a pivotal Phase 3 trial for CB-010 in 2L LBCL in H2 2025, pending confirmation of the HLA matching strategy [2][5] Corporate Updates - Sri Ryali was appointed as the new chief financial officer [1][11] - Caribou reported $281 million in cash, cash equivalents, and marketable securities as of September 30, 2024, providing a cash runway into H2 2026 [8] - The company expanded its leadership team with the appointments of Tim Kelly as chief technology officer and Tina Albertson, MD, PhD, as chief medical officer [11] Regulatory and Designations - CB-010 received Fast Track designation from the FDA for refractory systemic lupus erythematosus (SLE) and Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations for B cell non-Hodgkin lymphoma (B-NHL) [5][13] - CB-011 and CB-012 were granted Fast Track and Orphan Drug designations by the FDA for their respective indications [11][14][15] Scientific and Clinical Highlights - CB-010 demonstrated potential to match the safety, efficacy, and durability of approved autologous CAR-T cell therapies in the ANTLER Phase 1 trial [5] - Patients with ≥4 matching HLA alleles showed improved progression-free survival (PFS) in the ANTLER trial, prompting further enrollment to confirm the HLA matching strategy [5] - CB-011 is the first allogeneic CAR-T cell therapy with an immune cloaking strategy using a B2M knockout and B2M–HLA-E fusion protein insertion [14] - CB-012 is the first allogeneic CAR-T cell therapy with both checkpoint disruption (PD-1 knockout) and immune cloaking (B2M knockout and B2M–HLA-E fusion protein insertion) [15] Upcoming Events - Caribou will present at the 43rd Annual J P Morgan Healthcare Conference on January 16, 2025, at 10:30 am PST [1][10]

NEW YORK, Jan. 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou Biosciences, Inc." or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Caribou Biosciences, Inc. investors who were adversely affected by alleged securities fraud between July 14, 2023 and July 16, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ ...

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Caribou Biosciences, Inc. (NASDAQ: CRBU) between July 14, 2023 and July 16, 2024, both dates inclusive (the “Class Period”), of the important February 24, 2025 lead plaintiff deadline. SO WHAT: If you purchased Caribou securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem ...

SAN DIEGO, Jan. 9, 2025 /PRNewswire/ -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Caribou Biosciences, Inc. (NASDAQ: CRBU) securities between July 14, 2023 and July 16, 2024. Caribou is a clinical-stage biopharmaceutical company that purports to develop genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the U.S. and internationally.For more information, submit a form, email atto ...

NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU).Shareholders who purchased shares of CRBU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/caribou-biosciences-inc-loss-submission-form/?id=121489&from=4 CLASS PERIOD: Jul ...